Insilico AI candidate rentosertib reverses proteomic aging clocks
Insilico Medicine published a study in Nature Biotechnology reporting that its AI-designed idiopathic pulmonary fibrosis candidate rentosertib produced reductions in predicted biological age. The analysis used 12-week longitudinal Olink proteomic data from 42 patients enrolled in a Phase IIa trial a
<p>Insilico Medicine published a study in Nature Biotechnology reporting that its AI-designed idiopathic pulmonary fibrosis candidate rentosertib produced reductions in predicted biological age. The analysis used 12-week longitudinal Olink proteomic data from 42 patients enrolled in a Phase IIa trial a</p>